Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSHIT2)

Drug Name	PMID27774822-Compound-Figure9Example15 Drug Info
Cross-matching ID	TTD Drug ID DMSHIT2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting TYK2 tyrosine kinase (TYK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deucravacitinib	DMAR1YS	Plaque psoriasis	EA90.0	Approved	[2]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[2]
PF-06826647	DM5H8V1	Plaque psoriasis	EA90.0	Phase 2	[2]
PF-06826647	DM5H8V1	Plaque psoriasis	EA90.0	Phase 2	[3]
NDI-034858	DM2FJE7	Psoriatic arthritis	FA21	Phase 2	[4]
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[5]
PMID27774824-Compound-Figure9Example2down	DMXAV42	N. A.	N. A.	Patented	[5]
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[5]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[5]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
4	Clinical pipeline report, company report or official report of Nimbus Therapeutics
5	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.